Ana Giner Rubio - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ana Giner Rubio

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

The Journal of General Virology|May 17, 2015

Potyviruses differ in their requirement for TOR signallingLaurence Ouibrahim, Ana Giner Rubio, André Moretti, et al.

Clinical & Translational Immunology|February 9, 2022

Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.

Journal for Immunotherapy of Cancer|July 1, 2025

ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignanciesKevin P Nishimoto, Gauri Lamture, Yvan Chanthery, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

The Journal of General Virology|May 17, 2015

Potyviruses differ in their requirement for TOR signallingLaurence Ouibrahim, Ana Giner Rubio, André Moretti, et al.

Clinical & Translational Immunology|February 9, 2022

Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma modelsKevin P Nishimoto, Taylor Barca, Aruna Azameera, et al.

Journal for Immunotherapy of Cancer|July 1, 2025

ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignanciesKevin P Nishimoto, Gauri Lamture, Yvan Chanthery, et al.

Pageof 1